Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Bellmunt, J ^a   Orsola, A ^b   Maldonado, X ^b   Kataja, V ^c,d  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c VAASA CENTRAL HOSPITAL   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; PLATINUM COMPLEX; VINBLASTINE; VINFLUNINE;

ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER RECONSTRUCTION; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; CYSTECTOMY; DRUG RESPONSE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTECTOMY; CYSTOSCOPY; EUROPE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPH NODE EXCISION; META-ANALYSIS AS TOPIC; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PALLIATIVE CARE; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 77954338953     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq175     Document Type: Article

References (24)

1. Eble JN, Sauter G, Epstein JI et al. World Health Organization Classification of Tumors. Tumors of the Urinary System and Genital Organs. Pathology and Genetics. Lyon: IARC Press, 2004.
2. Epstein JI. The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement? Crit Rev Oncol Hematol 2003; 47: 83-89.
3. Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-314.
4. Divrik RT, Yildirim U, Zorlu F et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 2006; 175: 1641-1644.
5. Orsola A, Cecchini L, Raventos CX et al. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guerin therapy and the decision for a repeat TUR. BJU Int 2009; 205: 202-207.
6. Sylvester RJ, van der Meijden A, Witjes JA et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005; 66: 90-107.
7. Turner WH, Markwalder R, Perrig S et al. Meticulous pelvic lymphadenectomy in surgical treatment of the invasive bladder cancer: an option or a must? Eur Urol 1998; 33 (Suppl 4): 21-22.
8. Karl A, Carroll PR, Gschwend JE et al. The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. Eur Urol 2009; 55: 826-835.
9. Gospodarowicz MK, Blandy JP. Radiation therapy for organ-conservation for invasive bladder carcinoma. Baltimore: Lippincott, Williams and Wilkins, 2000.
10. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev. 2005; CD005246.
11. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Metaanalysis Collaboration. Eur Urol 2005; 48: 189-201.
12. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006; CD006018.
13. Bellmunt J, Hautmann RE. Open to debate. The motion: perioperative chemotherapy in muscle invasive bladder cancer improves survival. Eur Urol 2008; 54: 1192-1197.
14. Solsona E, Climent MA, Iborra I et al. Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 2008; 55: 911-919.
15. Shipley WU, Zietman AL, Kaufman DS et al. Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates-the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences. Semin Radiat Oncol 2005; 15: 36-41.
16. Herr HW. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2008; 54: 126-132.
17. Bellmunt J, de Wit R, Albiol S et al. New drugs and new approaches in metastatic bladder cancer. Crit Rev Oncol Hematol 2003; 47: 195-206.
18. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy. EORTC30987/Intergroup Study. ASCO Annual Meeting Proceedings part I. J Clin Oncol 2007.
19. De Santis M, Bellmunt J, Mead G et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer 'unfit' for cisplatin-based chemotherapy: phase II-results of EORTC Study 30986. J Clin Oncol 2009; 27: 5634-5639.
20. Schultz PK, Herr HW, Zhang ZF et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol 1994; 12: 1394-1401.
21. Fossa SD, Sternberg C, Scher HI et al. Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy. Br J Cancer 1996; 74: 1655-1659.
22. Bellmunt J, Maroto P, Mellado B et al. Phase II study of sunitinib as first line treatment in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy. ASCO Genitourinary Cancers Symposium 2008 (Abstr 291).
23. Bellmunt J, Theodore C, Demkov T et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinumcontaining regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-4461.
24. Maldonado J, Bellmunt J, Reyes V et al. Improvement in locoregional control rate adding radiotherapy in combination with chemotherapy in the handling of relapsed or incompletely resected transitional bladder cancer. Radiother Oncol 2004: 459.